America’s infectious disease doctor

Jeanne Marrazzo was the keynote speaker at Diploma Day 2024.

Jeanne Marrazzo (shown above) was the University of Pittsburgh School of Medicine Diploma Day keynote speaker on May 19.

In August 2023, Marrazzo, an MD, MPH, was named director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), a role previously held by Anthony Fauci, an MD.

At NIAID, Marrazzo oversees a $6.3 billion budget that supports research to advance understanding, diagnosis and treatment of infectious, immunologic and allergic diseases. She previously held the C. Glenn Cobbs Endowed Chair and served as director of infectious diseases at the University of Alabama at Birmingham Heersink School of Medicine.

As a researcher, Marrazzo’s specialties are the vaginal microbiome, sexually transmitted infections and HIV pre-exposure prophylaxis. She has had leadership roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium.

Marrazzo took time to share her thoughts on some of the most pressing issues facing science, on infectious disease threats, on lessons learned, as well as plenty of reasons for optimism during this “incredible time” for biomedicine.   —Interview by Erica Lloyd

What are you excited about moving forward as NIAID director?

It’s an incredible time. I would say in the next five years we have an unparalleled opportunity to change the trajectory of some diseases that have been incredibly stubborn.

The three that I think about a lot are tuberculosis, HIV and malaria.

For malaria, we have a couple of vaccines that have modest efficacy, but we are also now developing monoclonal antibodies that can be given very early in life, like at 10 months when kids lose their maternal antibodies. That’s a devastatingly vulnerable time for infants, for babies, for little kids.

If you could partner those monoclonal antibodies with a vaccine, we may be able to show at scale that a combination prevention and treatment program really works and start to reduce the number of deaths from malaria worldwide. Way too many kids, in particular, still die of malaria and cerebral malaria.

Regarding TB: We’ve been sort of at a standstill for a long time, but in the last five years we’ve started having promising developments in some drugs that are long-acting that can be used for both treatment and prevention. And the Gates Foundation recently embarked on a very large study of a TB vaccine that is a new biological model that has significant promise. Some ability to control TB would be amazing. It’s still the No. 1 killer of people living with HIV. There’s an outbreak in Los Angeles right now [May 2024] in which one person died, and a number of folks have been exposed. It’s definitely not something that is going away globally, in particular.

And the third one is HIV. We’ve done great in so many parts of the world getting treatment to people, and when people are adequately treated, they’re no longer able to transmit the virus to others. We’ve also done very well getting PrEP, pre-exposure prophylaxis, to people, but not well enough. There are still way too many perinatal transmissions worldwide.

And even in the United States, in the South, where I was most recently, and in challenged urban areas, we’re still seeing an incidence that is completely unacceptable, particularly in young men in the South—men who have sex with men.

And in South Africa, in young women, we’re still having very high rates.

We’re moving into an era where we now have better tools for prevention. We have long-acting injectables. We’re studying long-acting pills. And if you pair that with some of the advances in the vaccine and monoclonal antibody field, those may be closer to seven, eight, 10 years away. It comes together as a very encouraging picture for global prevention.

Speaking of HIV prevention, I understand that you led the VOICE study, which tested the efficacy of microbicide gels and pills to prevent HIV in women living in Africa. [Pitt’s Sharon Hillier directed the NIH Microbicide Trials Network, which included VOICE.] There was a big plot twist with that study. Women were reporting that they were adhering to the protocol—like thousands of them—when they weren’t. What was that like for you?

When we first realized what was happening, we were devastated.

It felt like a failure to demonstrate what we knew was being shown to be an effective biomedical intervention in other settings. It was working. It worked fantastically, particularly in couples in which one person had HIV and the other didn’t. It worked pretty well in men who have sex with men initially. And then when you started having on-demand use around potential exposures, it worked really well.

We also were devastated because it became very clear that the participants, for various reasons, would tell us they were taking PrEP consistently when in reality, they were not. And we ended up going in and talking to them.

We did a lot of work with our community members. And ultimately, what we showed is probably more important than what we would have shown if we’d just confirmed that that PrEP worked. There were two big lessons that our trial brought to the fore that changed the field:

One was you need biomarkers of adherence when you are asking very healthy people, especially, to take a product that they may not really be invested in taking, right? They may not really think that this is a product they need. Biomarkers can give us another data point to better understand how much people are using an intervention.

The second big lesson was that people stayed in the study because we gave them care. We gave them STI testing. We gave them contraception. We gave them counseling. There was an infrastructure that was essentially the equivalent of a primary care sort of health care system that probably many did not have such great access to.

So the lesson that I learned, and that I continue to carry with me, is that you really have to meet people where they’re at. You cannot just tell them to do something. And we learned this during the pandemic, right? Saying, “You must do this or else,” it’s really not the way things work for people.

And the women in our study were much more concerned about getting pregnant. Much more concerned about sexually transmitted infections. They knew about HIV, they knew it was a risk, but it was really not what was on their mind, at the forefront. So, lots of challenging lessons, but ultimately, incredibly valuable.

Can you talk about how that translates a little more to the pandemic example that you alluded to?

I think that people were getting all kinds of different messages during the COVID pandemic, and some of the messaging was coming from what should have been trusted authorities.

There was an element of, “I really don’t know who to believe. Furthermore, I didn’t trust you to start with, and now I really don’t trust you, because you can’t get your story straight.”

The burden has to be on us to communicate in a way that reaches people where they’re at. We, often, as scientists and physicians, just assume that because we think something is the right thing to do or the best thing to do, that everybody will just take our advice and believe it. I don’t think that’s true anymore. First of all, because you had a spectrum of opinions from physicians. There were plenty of people who were pushing therapies that we know from good evidence-based trials are completely ineffective and, in fact, sometimes harmful.

But why were people doing that? What were they seeking? Would it have made a difference to hear information from a peer? From somebody who was more representative of their communities? I don’t know. But all those questions are really important to talk about and engage with.

Are there any disease threats that keep you up at night? Like bird flu, or a new variant of COVID or measles?

All of it. There’s a baseline of infectious diseases that could come back and bite us at any time. Measles is a good example. Polio is a good example. These are things that we thought we had under control and, obviously, we’re not quite there.

So there’s a lot of vulnerability in some of those classic infectious diseases.

You can't talk about this without talking about respiratory viruses, even though people are, I think, a bit tired of hearing about the pandemic potential of respiratory viruses. But you can't forget the coronavirus has continued to evolve and even SARS-CoV-2 continues to evolve. There’s always a possibility that there will be enough immune evasion in that virus or another coronavirus that will cause a similar scenario.

Everybody’s really laser-focused on the avian influenza situation. We don’t really understand how cows became infected. At this moment, there’s no evidence of a very worrisome genetic mutation, but this virus is so crafty and has really established worldwide domination in the avian population very quickly.

So to see it spill over into cows and also into peridomestic animals like cats, that is worrisome.

No. 1, it increases the possibility for further pressure—for the virus to evolve, to adapt. No. 2, it increases opportunities for us humans to interact with these species.

And it increases the likelihood that you can involve another species, like pigs. Pigs are sort of the holy grail for influenza genetic reassortment, and we have been very nervous about this virus getting into pigs for quite a while. All of this is making many people in the public health world hypervigilant.

I wouldn’t say that people are raising the alarm bells to their highest level, but it is something we cannot ignore.

We’re all working very hard to ramp up our antiviral discoveries, as well as vaccines and monoclonal antibodies. Because we know that we have a stockpile that’s substantial, but we need to make sure we have plan B and C and D.

[Bird flu] is a tough foe. And we ignore, in particular, the massive die-offs we’re seeing of marine mammals at our peril, because that’s not normal. If it can create that kind of pathology in a new species—even if they’re harbor seals in Argentina, that most of us are not going to come in contact with—that should make you, me, everybody, alert.

The other thing I would say is that, although we have effective antivirals for respiratory viruses, we don't have any home runs. It’s not like an antibiotic that just wipes out a bacterial infection very quickly.

Thinking about pathogens and biosafety, where would you like discussions of gain-of-function research to land? [Gain-of-function research refers to changing a pathogen in a lab to study it, sometimes making it more infectious or virulent, to prepare to respond to threats from it.]

I would say a couple of things. One is that we operate in an environment where we trust good scientists to do good science and safe science. And what that means is that you have the appropriate biosafety level in your lab, that you have people who are appropriately trained, that you have a very good reason and rationale to do the work, and that the case has been effectively made, vetted and approved to do this type of research.

The gain-of-function term can be applied to experiments that are often critical to understanding the functional roles, particularly that genes play, in pathogens. So the trade-off here is ensuring that there’s a really robust scientific rationale for what you’re doing, and that there’s really no other way you can do it. Of course, again, these types of experiments aren’t done in a vacuum—they have to be proposed, reviewed and approved for them to be conducted in the first place.

That’s the key, right? That it’s going to advance our knowledge of that particular pathogen in a way that’s going to inform our ability to intervene, whether it’s through a treatment or prevention, such as a vaccine.

Certainly, if you can’t do that, and especially if you can’t do it in a safe environment, then you don’t have any business doing it, and it’s not going to get approved. The bar is set very high for this type of research, as it should be. That is the spirit in which we operate, and that’s what we expect of our grantees.

It’s become a hotly discussed topic. It has kind of taken on a life of its own, which creates the potential for scaring good scientists away from such work. The reality is we need the research pipeline to be healthy. We need people to be doing work with pathogens that could potentially be our next big foe.

[The U.S. Office of Science and Technology Policy released a revised policy on federal funding for such research shortly after Dr. Marrazzo spoke with us.]

The well is not as deep as the need in terms of funding for science generally. Physician-scientists and PhDs may feel like they’re fighting for their research lives. Where do we go from here?

It’s complicated. It’s time to start looking at these things. [We’ll be] committing to making sure that our training budget reflects the need to keep this pipeline healthy—whether it’s PhDs, MDs or other people.

Part of the challenge is that training is not the same as when I was going through this. At that time, we expected to be in training for a long time, but not forever. And we also didn’t expect to be in debt in the same way, like hundreds of thousands of dollars. So, we’re asking people to live a model that is almost no longer tenable.

For example, the average age of somebody getting their first R01 right now, which is an independent research award from NIH, it’s like 40. That’s delayed gratification.

We have to look very hard at the disincentives. We’ve relied for a long time on the incentives, right? Because we think it’s fantastic. It’s fun. Science is great—we’re making a difference. But there are some disincentives to getting into this work, especially for investigators who are looking at a research career.

What should new grads going into medicine be optimistic about?

In addition to what I’ve mentioned, I think that evolving technology is probably going to make life better, easier and more interesting. So when I say that, I mean the technology for interventions for developing cancer drugs, for imaging, for developing vaccines. Those technical tools are just going to keep getting better and better because the pace of discovery is really quick right now.

The other thing is, I hope that some of the drudgery that has characterized the last 20 years of shifting to the electronic medical record is likely to be relieved by AI. For every five minutes you spend with a patient, you spend [about] 20 on documentation. It’s really hard to have a meaningful eye-to-eye contact conversation and also keep up with all this other stuff.

In terms of new tools: Cancer treatment is just completely amazing right now [for] people who would once have had death sentences [from a diagnosis]. We may not have a cure, but we are getting better and better at individualized therapy and figuring out how to give people meaningful quality of life.

I also think that the recent pig-to-human kidney xenotransplantation is pretty amazing. They basically took all the porcine retroviruses out of that pig using CRISPR. The ability to carefully curate what you’re doing as you transplant an organ—it’s a game changer.

What would your advice be to new doctors generally—whether they’re going into research or clinical practice or both in this polarized environment where medical authorities aren’t necessarily trusted anymore? And then there are, of course, populations who didn’t really trust them all along.

If you’re doing what you love, and you feel like you’re making a difference and having an impact on people’s lives, you really can’t go wrong. You could be in research. You could be in clinical practice. You could be working for a pharmaceutical company. You could be doing global health and working with a nonprofit. You could go into policy. If you’re bringing your best self to whatever is happening at that moment, and that’s translating to an enhancement of someone’s life—

There are so many interactions I’ve had, particularly with patients, that have refueled me and mean so much more than some of the more traditional honors that I’ve gotten. Those are the things I think about when I’m feeling like, “Oh my gosh, I really can’t do this again.”

I don’t think about the awards. I think about my patients, and I think about my trainees, my students. That’s what really keeps me motivated.

Thank you so much.

Read more from the Fall 2024 issue.